DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Teveten HCT (Eprosartan Mesylate / Hydrochlorothiazide) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, TEVETEN® HCT Tablets should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

TEVETEN HCT SUMMARY

TEVETEN® HCT 600/12.5 mg and TEVETEN® HCT 600/25 mg (eprosartan mesylate-hydrochlorothiazide) combine an angiotensin II receptor (AT1 subtype) antagonist and a diuretic, hydrochlorothiazide. TEVETEN® (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist.

TEVETEN® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).


See all Teveten HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Hard-to-treat hypertension may jeopardize sleep apnea patients' heart health
Source: Cardiovascular / Cardiology News From Medical News Today [2016.07.19]
In a study of patients with hypertension, those with resistant hypertension - meaning that their blood pressure remained elevated despite concurrent use of three antihypertensive agents of...

Stroke is largely preventable, with hypertension confirmed as biggest risk factor, according to global study
Source: Hypertension News From Medical News Today [2016.07.18]
Ten potentially modifiable risk factors account for 90% of strokes worldwide, but regional variation should be considered, says study.

Prehypertension during pregnancy could lead to cardiovascular risks
Source: Hypertension News From Medical News Today [2016.06.28]
Pregnant women who experience persistent blood pressure elevations in the upper ranges of normal may be at high risk of developing metabolic syndrome and increased cardiovascular risk after giving...

Blood test shows promise in gauging severity of pulmonary arterial hypertension
Source: Respiratory / Asthma News From Medical News Today [2016.06.22]
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial...

The healing powers of music: Mozart and Strauss for treating hypertension
Source: Hypertension News From Medical News Today [2016.06.21]
The music of Mozart and Strauss is able to lower blood lipid concentrations and the heart rate.

more news >>

Published Studies Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial). [2010.06]
INTRODUCTION: Systolic hypertension is very common in the elderly and is strongly associated with the risk of cardiovascular and cerebrovascular events. The control of systolic hypertension is difficult and most patients require combination antihypertensive therapy. Few data are available regarding the efficacy of angiotensin II receptor antagonists on systolic hypertension of the elderly. The aim of this double-blind, double-dummy, randomized, parallel-group, multicenter study was to assess the efficacy of eprosartan 600 mg in combination with hydrochlorothiazide (HCTZ) 12.5 mg in comparison with losartan 50 mg in combination with HCTZ 12.5 mg, in reducing blood pressure in elderly patients with grade 2 systolic hypertension who did not optimally respond to eprosartan or losartan monotherapy... CONCLUSION: In this study, eprosartan/HCTZ did not demonstrate to be superior to losartan/HCTZ in reducing ABPM systolic hypertension in the elderly.

Safety and tolerability of eprosartan in combination with hydrochlorothiazide. [2002]
The ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects... Therefore, the combination of eprosartan with hydrochlorothiazide can be effectively and safely used in patients not adequately responding to eprosartan monotherapy.

more studies >>

Clinical Trials Related to Teveten HCT (Eprosartan / Hydrochlorothiazide)

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension [Completed]
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers [Completed]
The purpose of this study is to find out how chemicals in the blood of patients with chronic kidney disease affect how medications are removed from the body. The patient will take one dose of three different drugs, one on each week, for a total of three single doses. The investigators want to find out if these three different medications are affected in different ways by the chemicals in the blood of patients with kidney disease.

The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans. [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan

reduces the activity of the sympathetic nervous system in healthy individuals - during

baseline conditions and after activation of the sympathetic nervous system.

Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes [Completed]

The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension [Completed]
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential

hypertension - during baseline conditions and after activation of the sympathetic nervous

system.

more trials >>


Page last updated: 2016-07-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015